Abstract
BackgroundMethotrexate (MTX) is recommended as the first-line disease modifying anti-rheumatic drug (csDMARD) for the treatment of rheumatoid arthritis (RA), but up to 40% patients do not respond adequately, or experience...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have